SMC Approves Tibotec’s Prezista For Use In NHS Scotland
The Scottish Medicines Consortium (SMC) has approved Tibotec’s once daily Prezista (darunavir) for use within NHS Scotland. Darunavir is a protease inhibitor (PI) indicated for the treatment of
SK bioscience is set to lead the Gates Foundation-fundedResearch Optimization & Trial Outcome Recommender (ROTOR) project, an AI-based platform aimed at reducing uncertainty in vaccine-development decisions.